AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease (CD). Presented at the American College of Gastroenterology 2026 Annual Scientific Meeting, the findings build on the previously reported efficacy results of subcutaneous (SC) SKYRIZI® treatment, showing new endoscopic remissionii and ulcer-free endoscopyiii outcomes for patients receiving SKYRIZI subcutaneously.i 

After treatment with SKYRIZI, 35.8% of patients achieved endoscopic remission, or the healing of the intestinal lining with little to no visible inflammation.i Across subgroups, 36.6% of patients who had ulcers at the start of the study achieved the complete absence of ulcers, known as ulcer-free endoscopy, after induction and maintenance treatment.i Among advanced therapy-naïve patients, rates were higher, with 45.1% achieving endoscopic remission and 49.0% achieving ulcer-free endoscopy, representing the highest rates observed across the evaluated subgroups

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.